Literature DB >> 12727944

Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study.

Fausto Bogazzi1, Luigi Bartalena, Chiara Cosci, Sandra Brogioni, Enrica Dell'Unto, Lucia Grasso, Fabrizio Aghini-Lombardi, Giuseppe Rossi, Aldo Pinchera, Lewis E Braverman, Enio Martino.   

Abstract

Amiodarone-induced thyrotoxicosis (AIT) may occur either in the presence of underlying thyroid disease (type I AIT) or in apparently normal thyroid glands (type II AIT). Type II AIT, a destructive thyroiditis, often favorably responds to glucocorticoids. Iopanoic acid (IopAc) is an iodinated cholecystographic agent that inhibits deiodinase activity and reduces the conversion of T(4) toT(3). It has recently been reported that cholecystographic agents restore euthyroidism in patients with type II AIT. We describe the results of a prospective randomized study conducted in 12 patients with type II AIT treated with either iopanoic acid (group A, n = 6) or glucocorticoids (group B, n = 6). Serum free T(3) levels normalized rapidly in both groups after 7 d, from 0.75 +/- 0.20 ng/dl (11.5 +/- 3.1 pmol/liter) to 0.46 +/- 0.10 ng/d (7.1 +/- 1.7 pmol/liter), P < 0.01, and from 0.58 +/- 0.10 ng/dl (9.0 +/- 1.2 pmol/liter) to 0.34 +/- 0.03 ng/dl (5.2 +/- 0.5 pmol/liter), P < 0.003, in groups A and B, respectively (P = NS). Serum free T(4) levels reduced at 6 months in group B [from 2.70 +/- 0.32 ng/dl (35.1 +/- 4.1 pmol/liter) to 1.0 +/- 0.04 ng/dl (13.4 +/- 0.6 pmol/liter), P < 0.0001] but not in group A (from 2.90 +/- 0.6 ng/dl (38.0 +/- 7.5 pmol/liter) to 2.30 +/- 0.4 ng/dl (35.6 +/- 6.1 pmol/liter, P = 0.39; P = 0.005 group B vs. group A). All patients in both groups became euthyroid and had their amiodarone-induced destructive thyroiditis cured as defined by normalization of both serum free T(4) and free T(3) levels, during both drugs therapy. However, patients in group B were cured more rapidly than patients in group A (43 +/- 34 d vs. 221 +/- 111 d, respectively, P < 0.002). This study shows that, albeit both drugs are effective, glucocorticoids are probably the drug of choice for more rapidly curing type II AIT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727944     DOI: 10.1210/jc.2002-021874

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 amiodarone-induced thyrotoxicosis.

Authors:  L Tomisti; C Urbani; G Rossi; F Latrofa; C Sardella; L Manetti; I Lupi; C Marcocci; L Bartalena; O Curzio; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2016-01-13       Impact factor: 4.256

Review 2.  Amiodarone and the thyroid: a 2012 update.

Authors:  F Bogazzi; L Tomisti; L Bartalena; F Aghini-Lombardi; E Martino
Journal:  J Endocrinol Invest       Date:  2012-03-19       Impact factor: 4.256

3.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

Review 4.  A review of species differences in the control of, and response to, chemical-induced thyroid hormone perturbations leading to thyroid cancer.

Authors:  John R Foster; Helen Tinwell; Stephanie Melching-Kollmuss
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

Review 5.  [Clinical aspects of treatment with amiodarone].

Authors:  W Haverkamp; C Israel; A Parwani
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-09

Review 6.  Effects of amiodarone therapy on thyroid function.

Authors:  Janna Cohen-Lehman; Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

7.  Amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge.

Authors:  Umang Barvalia; Barkha Amlani; Ram Pathak
Journal:  Case Rep Med       Date:  2014-11-12

8.  Endocrine system dysfunction and chronic heart failure: a clinical perspective.

Authors:  Giuseppe Lisco; Vito Angelo Giagulli; Michele Iovino; Roberta Zupo; Edoardo Guastamacchia; Giovanni De Pergola; Massimo Iacoviello; Vincenzo Triggiani
Journal:  Endocrine       Date:  2021-10-28       Impact factor: 3.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.